Viking Therapeutics, INC 8-K filings

Viking Therapeutics reported strong progress in its Q2 2026 results, with key obesity drug trials fully enrolled and advancing, alongside a robust cash position.

Viking Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Viking Therapeutics announced its Q4 and full-year 2025 financial results, alongside significant progress in its obesity drug pipeline, including plans for Phase 3 trials for oral VK2735 and ongoing subcutaneous VK2735 studies.

Viking Therapeutics reported its third quarter 2025 financial results, highlighting significant progress in its obesity drug pipeline with VK2735 subcutaneous and oral formulations, despite increased net losses.

Viking Therapeutics announced positive top-line Phase 2 results for its oral VK2735 tablet, demonstrating statistically significant weight reductions in obesity patients.

Viking Therapeutics announced its second quarter 2025 financial results, highlighting the initiation of Phase 3 trials for subcutaneous VK2735 in obesity and completion of enrollment for the oral VK2735 Phase 2 study, alongside increased net losses.

Viking Therapeutics, Inc. announced the successful passage of all three proposals at its 2025 Annual Meeting of Stockholders, including the re-election of two Class I directors, ratification of its independent auditor, and advisory approval of executive compensation.

Viking Therapeutics reports a strong cash position of $852 million and progress in its VK2735 obesity program, with Phase 3 trials expected to begin in Q2 2025 and Phase 2 oral dosing trial data anticipated in 2H25.

Viking Therapeutics replaces Marcum LLP with CBIZ CPAs P.C. as its independent registered public accounting firm due to CBIZ's acquisition of Marcum's attest business.

Viking Therapeutics has entered into a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ensuring sufficient supply for potential multi-billion-dollar annual product opportunity.

Viking Therapeutics reports strong year-end cash position of $903 million and plans to initiate Phase 3 studies for subcutaneous VK2735 for obesity in 2Q25.

Viking Therapeutics reported promising data from its VK2735 obesity program, including significant weight loss with both oral and subcutaneous formulations.

Viking Therapeutics reported positive financial results for the third quarter of 2024, along with significant progress in its clinical programs, including obesity and NASH/MASH treatments.

Viking Therapeutics reported positive results from multiple clinical trials and provided a corporate update, including plans to advance VK2735 into Phase 3 development for obesity.

Viking Therapeutics reports positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809, showing significant improvements in NASH resolution and fibrosis.

Viking Therapeutics' stockholders approved the 2024 Equity Incentive Plan and the 2024 Employee Stock Purchase Plan at the company's annual meeting on May 21, 2024.

Viking Therapeutics reported positive results from its Phase 2 VENTURE trial for VK2735, a dual GLP-1/GIP agonist, and completed a $630 million public offering.

Viking Therapeutics reports successful Phase 1 trial results for its oral weight loss drug, VK2735, showing significant placebo-adjusted weight loss and good tolerability.

Viking Therapeutics successfully closed a public offering of common stock, raising approximately $632.5 million to fund its clinical programs and general operations.

Viking Therapeutics has announced the pricing of a $550 million public offering of its common stock to fund continued development of its drug programs and for general corporate purposes.

Viking Therapeutics' VK2735 demonstrated significant weight loss in a Phase 2 trial, achieving primary and secondary endpoints with up to 13.1% placebo-adjusted mean weight loss.

Viking Therapeutics reported its fourth quarter and full-year 2023 financial results, highlighted by a strong cash position of $362 million and progress across its clinical programs.